40 results about "Phage therapy" patented technology

Purified, host-specific, non-toxic, wide host range and virulent bacteriophage preparations that are effective in killing bacterial organisms in vivo are disclosed. Also disclosed are compositions containing these bacteriophages, methods of making the bacteriophage preparations and methods of treating bacterial infections using the compositions. Methods of treating bacterial infections using the compositions containing the bacteriophages in combination with conventional antibiotics also are disclosed.

The invention relates to the field of microbes and provides a novel salmonella phage and a composition, a preparation method and application thereof. The novelsalmonella phage is Myoviridaesp. BP-66 with the preservation numberCCTCC NO: M2015146,Myoviridaesp. BP-63 with preservation number CCTCC NO: M2015145, or Chilikevirussp. BP-12 with the preservation number CCTCCNO: M2015141. The novel phage is a strict virulent phage, has high toxicity to host bacteria, has a wider host range and still has high toxicity to the host bacteria at low concentration. The DNA of the phage cannot encode protein possibly causing potential health risks. The novel phage stably survives in a culture solution at room temperature and survive for more than 6 months at the temperature below 4 DEG C. In addition, the phage can be proliferated on pathogenic bacterial hosts, and large-scale industrial production can be achieved. The salmonella phage can provide excellent strain resources for application of phage therapy.

The objective of the present invention is to provide chimeric phage-derived particles, that may be used as safe food grade vehicles to for presenting various factors (e.g. antigens, virulence proteins, receptors, ligands, etc.) for living cells. In addition to at least one normal phage or virus component the particles comprise at least one additional factor that is not encoded by the genetic material of the chimeric particle. Applications for such particles include, but are not limited to, vaccine development, pathogen neutralization, chemical binding and / or neutralization (e.g. toxins), and competitive exclusion. In addition, this technology may be used to extend the retention time of phage particles during phage therapy and / or specifically target a given particle for a biofilm.

The present invention relates to the use of bacteriophages to treat infections diseases. The invention provides a method for intermediate to large scale commercial production of bacteriophage composition, wherein the method reduces the production volume and elevates production yield. The invention further relates to improved bacteriophage compositions comprising specific sugars that reduce or abolish the bacterial phage-neutralizing activity.

The present invention generally relates to engineered bacteriophages which express amyloid peptides for the modulation (e.g. increase or decrease) of protein aggregates and amyloid formation. In some embodiments, the engineered bacteriophages express anti-amyloid peptides for inhibiting protein aggregation and amyloid formation, which can be useful in the treatment and prevention of and bacterial infections and biofilms. In some embodiments, the engineered bacteriophages express amyloid peptides for promoting amyloid formation, which are useful for increasing amyloid formation such as promoting bacterial biofilms. Other aspects relate to methods to inhibit bacteria biofilms, and methods for the treatment of amyloid related disorders, e.g., Alzheimer's disease using an anti-amyloid peptide engineered bacteriophages. Other aspects of the invention relate to engineered bacteriophages to express the amyloid peptides on the bacteriophage surface and / or secrete the amyloid peptides, e.g., anti-amyloid peptides and pro-amyloid peptides, and uses thereof for modulation protein aggregates and amyloid formation.

The present invention relates to a novel bacteriophage having an E.-coli-specific bactericidal activity, a composition for the prevention or treatment of infectious diseases caused by Enterotoxigenic E.-coli comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, a feed additive composition comprising the bacteriophage as an active ingredient, a sanitizer or cleaner comprising the bacteriophage as an active ingredient, and a method for treating colibacillosis using the bacteriophage. The novel bacteriophage of the present invention has a specific bactericidal activity against pathogenic E. coli, and excellent acid- and heat-resistance. Therefore, the novel bacteriophage can be used for the prevention or treatment of swine colibacillosis, which is an infectious disease caused by pathogenic E.-coli, and can also be widely used in animal feed additive compositions, sanitizers, and cleaners.

The invention relates to an aeromonas salmonicida phage, a bactericidal composition comprising the same and an application of the bactericidal composition. The phage is capable of quickly inhibiting growth of Atlantic aeromonas salmonicida within a short period of time and inhibiting generation of resistance of the pathogenic bacterium phage. In addition, the bactericidal composition comprising the phage is safe and effective, and is high in specificity and low in production cost, and the disadvantages of single phagotherapy are compensated in the control process of pathogenic bacterium.

The invention belongs to the technical field of research and development of vibrio alginolyticus phage, and in particular, relates to an alkali-resistant vibrio alginolyticus phage and a composition thereof, and a kit. The vibrio alginolyticus phage is vibrio alginolyticus phage VAP21, and has the preservation number of CCTCC NO:M 2018768. The invention also discloses an application of the vibrioalginolyticus phage, or a vibrio alginolyticus phage composition, or a reagent or kit containing the vibrio alginolyticus phage or the vibrio alginolyticus phage composition in killing and / or preventing vibrio microorganisms. The vibrio alginolyticus phage has wide host range, still has high toxicity to host bacteria at low concentration, good proliferation on non-pathogenic bacteria host and large-scale industrial production, and can provide excellent strain resources for an application of phagotherapy.

The invention relates to a vibrio parahaemolyticus phage and a bactericidal composition containing the same. The phage can rapidly inhibit the growth of vibrios in a short time, and the duration of inhibition lasts long. In addition, the bactericidal composition of the phage is safe and effective, has strong specificity, is low in production cost, and makes up for the shortcoming of single phagotherapy in the control process of pathogenic bacteria.

The invention belongs to the technical field of research and development of Vibrio alginolyticus phages and particularly relates to a wide-lytic-spectrum Vibrio alginolyticus phage, composition thereof, and a kit. The wide-lytic-spectrum Vibrio alginolyticus phage is Vibrio alginolyticus phage VAP7 collected under CCTCC NO: M 2018767. The inventio also discloses application of the Vibrio alginolyticus phage, a Vibrio alginolyticus phage composition, or a reagent or a kit containing the Vibrio alginolyticus phage or the Vibrio alginolyticus phage composition in the killing and / or prevention ofVibrio microbes. The Vibrio alginolyticus phage herein has a wide host range, has high toxicity to host bacteria under low concentration, can well propagate on nonpathogenic bacterial hosts, and is suitable for large-scale industrial production. Good strain resources can be provided for the application of phagotherapy.

The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular diabetic foot infections. More specifically, the present invention is directed to novel cocktails of bacteriophage strains F44 / 10, F1 25 / 10, F770 / 05, F510 / 08, F1 245 / 05, and / or variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including cutaneous ulcers associated with diabetic foot infections, caused by, e.g., Staphylococcus aureus, Pseudomonas aeruginosa, and / or Acinetobacter baumannii. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics, growth factors, or other standard, as well as non-standard, therapies for diabetic foot infections.

The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245 / 05, F168 / 08, F170 / 08, F770 / 05, F197 / 08, F86 / 06, F87s / 06 and F91a / 06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and / or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.

The invention relates to an aeromonas salmonicida phage, a bactericidal composition containing the aeromonas salmonicida phage and application of the aeromonas salmonicida phage and the bactericidal composition. The phage can rapidly inhibit the growth of Atlantic aeromonas salmonicida in a short time and inhibit the generation of resistance to the pathogenic bacterium phage. In addition, the bactericidal composition of the phage is safe and effective and is high in specificity, the production cost is low, and the defects of a single phage therapy in a pathogen control process are made up.

The invention relates to Aeromonas salmonicida phage, a bactericidal composition containing the same and application of the same. The Aeromonas salmonicida phage may inhibit the growth of Atlantic Aeromonas salmonicida quickly within a short time, and inhibit the occurrence of resistance in the phage. In addition, the bactericidal composition containing the Aeromonas salmonicida phage is good in safety and effect, high in specificity and low in production cost, and the defects of single phage therapy during control of pathogenic bacteria are made up.

The present invention relates to a novel bacteriophage having an E. coli-specific bactericidal activity, a composition for the prevention or treatment of infectious diseases caused by Enterotoxigenic E. coli comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, a feed additive composition comprising the bacteriophage as an active ingredient, a sanitizer or cleaner comprising the bacteriophage as an active ingredient, and a method for treating colibacillosis using the bacteriophage. The novel bacteriophage of the present invention has a specific bactericidal activity against pathogenic E. coli, and excellent acid- and heat-resistance. Therefore, the novel bacteriophage can be used for the prevention or treatment of swine colibacillosis, which is an infectious disease caused by pathogenic E. coli, and can also be widely used in animal feed additive compositions, sanitizers, and cleaners.

The invention discloses staphylococcus aureus bacteriophage and application. The staphylococcus aureus bacteriophage and the application have the advantages that staphylococcus aureus can be specifically effectively eliminated by the staphylococcus aureus bacteriophage, excellent in-vivo and in-vitro antibacterial effects can be realized by the staphylococcus aureus bacteriophage for medicine-resistant staphylococcus aureus, experimental foundations can be provided to clinically developing preparations for preventing and treating medicine-resistant staphylococcus aureus infection, and the staphylococcus aureus bacteriophage has great clinical application potential; the skin abscess average areas of nude mice of bacteriophage treatment groups are 47.32 mm<2> in skin abscess models when MOI(multiplicity of infection) is equal to 10, and the average bacterium load is 3.553*10<7> CFU / g; the skin abscess average areas of nude mice of MRSA (methicillin-resistant staphylococcus aureus) infection groups are 150.4 mm<2>, and the average bacterium load is 2.284*10<8> CFU / g; the skin abscess areas of the mice of the bacteriophage treatment groups are smaller than the skin abscess areas of the mice of the MRSA infection groups, the colony count of the mice of the bacteriophage treatment groups is lower than the colony count of the mice of the MRSA infection groups, and the difference of the skin abscess areas and the colony count has statistical significance.

The present invention relates to a bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia colis trains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.

The invention relates to lytic vibrio phage ValDsh-1, a sterilization composition containing the phage and application of the lytic vibrio phage ValDsh-1 and the sterilization composition. The phage can fast inhibit the growth of vibrio within a short time; in addition, the inhibition effect can be maintained for a long time. In addition, the sterilization composition of the phage is safe, effective, high in specificity and is low in production cost; in the pathogen control process, the defects of a single phage treatment method are overcome.

The invention relates to use of one or more bacteriophages in vivo in a human or animal in order to induce sensitivity to chemical antibiotics in bacterial cells, where such susceptibility is heritable, independent of continuing bacteriophage metabolism within those cells, and does not relate to the destruction of a biofilm to induce such sensitivity.

The invention belongs to the technical field of research and development of vibrio alginolyticus phage and particularly relates to a high temperature resistant vibrio alginolyticus phage, as well as acomposition and kit thereof. The vibrio alginolyticus phage VAP9 has a preservation number of CCTCC NO:M 2018766. The invention further discloses application of the vibrio alginolyticus phage, or a vibrio alginolyticus phage composition, or a reagent or kit containing the vibrio alginolyticus phage or vibrio alginolyticus phage composition in killing and / or preventing vibrio microbes. The vibrioalginolyticus phage has a wide host range, still has high toxicity on host bacteria under a low concentration, can be well reproduced on a nonpathogenic bacterial host and can realize large-scale industrial production. an excellent strain resource can be provided to application of phagotherapy.

The invention relates to a lytic vibrio phage ValLY-4, a bactericidal composition containing the same and application thereof. The phage can rapidly inhibit vibrio growth within a short time, and theinhibiting effect lasts for a long time. In addition, the bactericidal composition of the phage is safe and effective, also has strong specificity, is low in production cost, and makes up for the shortcomings of single phage therapy in the control process of pathogenic bacteria.

The invention relates to the field of microorganisms, and provides a novel salmonella phage, a composition thereof, and a preparation method and application thereof. The novel salmonella phage is a myoviridae BP-66, the preservation number is CCTCC NO: M2015146, the preservation number of the myoviridae BP-63 is CCTCC NO: M2015145, the preservation number of chilikevirus BP-12 is CCTCC NO: M2015141. The novel bacteriophage is a strict virulent bacteriophage, has high toxicity to host bacteria, has a wide host range, and still has high toxicity to the host bacteria at low concentration; the DNAof the phage cannot encode protein that can pose a potential health risk; the bacteriophage stably survive in a culture solution at room temperature, and can live for more than 6 months below 4 DEG C; the bacteriophage can be well proliferated on a non-pathogenic bacterial host; large-scale industrial production can be achieved. The salmonella phage can provide excellent strain resources for theapplication of phage therapy.

The invention relates to a vibrio alginolyticus phage and a bactericidal composition containing the same. The phage can rapidly inhibit vibrio growth in a short time, and the inhibition effect lasts long. In addition, the bactericidal composition of the phage is safe and effective, has strong specificity, and is low in production cost, and makes up for the shortcomings of single phage therapy in the control process of pathogenic bacteria.

The invention relates to a lytic vibrio phage VspSw-1, a bactericidal composition containing the same and application thereof. The phage can rapidly inhibit vibrio growth within a short time, and theinhibiting effect lasts for a long time. In addition, the bactericidal composition of the phage is safe and effective, also has strong specificity, is low in production cost, and makes up for the shortcomings of single phage therapy in the control process of pathogenic bacteria.

The present invention relates to phage isolates having a strong lytic activity against pathogenic Enterobacteriaceae such as Escherichia coli and / or Salmonella strains and their use in various human or pet food products for the treatment or prevention of bacterial diseases caused by pathogenic Enterobacteriaceae such as Escherichia coli , in particular for phage therapy of pediatric gastroenteritis, or Salmonella infection. It also relates to human or pet food products prepared thereof.

The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.

The invention relates to a lytic vibrio phage ValLY-3, a bactericidal composition containing the same and application thereof. The phage can rapidly inhibit vibrio growth within a short time, and theinhibiting effect lasts for a long time. In addition, the bactericidal composition of the phage is safe and effective, also has strong specificity, is low in production cost, and makes up for the shortcomings of single phage therapy in the control process of pathogenic bacteria.

The invention relates to functions of genes of pseudomonas aeruginosa and an application of the genes, wherein the gene BN889_05221, the gene PA0243, the gene PA3808, the gene PA1993 and the gene PA1115 of pseudomonas aeruginosa are the necessary host genes of phage infection, and are used for screening the relevant medicines for inhibiting the phage infection. According to the invention, through the study on the relevant host genes of phage infection, a molecular mechanism for the interaction between phage and host bacteria can be well understood, therefore, a theoretical basis is provided for the treatment on the phage, meanwhile, new target genes related to virus infection can be found, and assistance is provided for screening antiviral drugs.

The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245 / 05, F168 / 08, F170 / 08, F770 / 05, F197 / 08, F86 / 06, F87s / 06 and F91a / 06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and / or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.

The invention relates to functions of genes of pseudomonas aeruginosa and an application of the genes, wherein the gene BN889_05221, the gene PA0243, the gene PA3808, the gene PA1993 and the gene PA1115 of pseudomonas aeruginosa are the necessary host genes of phage infection, and are used for screening the relevant medicines for inhibiting the phage infection. According to the invention, through the study on the relevant host genes of phage infection, a molecular mechanism for the interaction between phage and host bacteria can be well understood, therefore, a theoretical basis is provided for the treatment on the phage, meanwhile, new target genes related to virus infection can be found, and assistance is provided for screening antiviral drugs.